Patents Issued in January 3, 2017
-
Patent number: 9533004Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Dystrophin family, in particular, by targeting natural antisense polynucleotides of Dystrophin family. The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of DMD family.Type: GrantFiled: December 9, 2014Date of Patent: January 3, 2017Assignee: CuRNA, Inc.Inventors: Joseph Collard, Olga Khorkova Sherman
-
Patent number: 9533005Abstract: A modified starch material for biocompatible hemostasis, biocompatible adhesion prevention, tissue healing promotion, absorbable surgical wound sealing and tissue bonding, when applied as a biocompatible modified starch to the tissue of animals. The modified starch material produces hemostasis, reduces bleeding of the wound, extravasation of blood and tissue exudation, preserves the wound surface or the wound in relative wetness or dryness, inhibits the growth of bacteria and inflammatory response, minimizes tissue inflammation, and relieves patient pain. Any excess modified starch not involved in hemostatic activity is readily dissolved and rinsed away through saline irrigation during operation. After treatment of surgical wounds, combat wounds, trauma and emergency wounds, the modified starch hemostatic material is rapidly absorbed by the body without the complications associated with gauze and bandage removal.Type: GrantFiled: July 2, 2014Date of Patent: January 3, 2017Inventor: Xin Ji
-
Patent number: 9533006Abstract: Marine coatings including cationic polymers hydrolyzable to nonfouling zwitterionic polymers, coated marine surfaces, and methods for making and using the marine coatings.Type: GrantFiled: December 3, 2012Date of Patent: January 3, 2017Assignee: University of WashingtonInventors: Shaoyi Jiang, Xuewei Xu, Yuting Li, Andrew Keefe, Hong Xue, Shengfu Chen
-
Patent number: 9533007Abstract: A process for making nanoparticles of biocompatible materials is described, wherein an aqueous reaction mixture comprising cerous ion, citric acid and ethylenediaminetetraacetic acid in a predetermined ratio, an oxidant, and water is provided along with temperature conditions to directly form, without isolation, a stable dispersion of cerium oxide nanoparticles. These biocompatible cerium oxide nanoparticles may be used to prevent and/or treat oxidative stress related diseases, such as stroke, relapse/remitting multiple sclerosis, chronic-progressive multiple sclerosis, amyotrophic lateral sclerosis, and ischemic reperfusion injury.Type: GrantFiled: April 20, 2015Date of Patent: January 3, 2017Assignee: CERION, LLCInventors: Kenneth Joseph Reed, Wendi Ann Costanzo, Joseph Samuel Erlichman, Eric Leslie Bell
-
Patent number: 9533008Abstract: The present invention can supply a pulse to a pure germanium rod made of germanium so as to significantly increase concentration in a short period of time and shorten dissolving time, and relates to a device for generating and supplying germanium ionic water, which can promote the ionization of germanium.Type: GrantFiled: September 26, 2014Date of Patent: January 3, 2017Inventor: Dong Huen Kim
-
Patent number: 9533009Abstract: Human progenitor T cells that are able to successfully engraft a murine thymus and differentiate into mature human T and NK cells are described. The human progenitor T cells have the phenotype CD34+CD7+CD 1a?CD5? or CD34+CD7+CD1a?CD5+ and are derived from human hematopoietic stem cells, embryonic stem cells and induced pluripotent stem cells by coculture with cells expressing a Notch receptor ligand (OP9-DL1 or OP9-DL4). Such cells are useful in a variety of applications including immune reconstitution, the treatment of immunodeficiencies and as carriers for genes used in gene therapy.Type: GrantFiled: May 22, 2014Date of Patent: January 3, 2017Assignee: Sunnybrook Health Sciences CentreInventors: Juan Carlos Zuniga-Pflucker, Geneve Awong, Ross La Motte-Mohs
-
Patent number: 9533010Abstract: The described invention provides methods and regimens for treating adverse consequences of a persistent and progressive myocardial injury-due to a vascular insufficiency that occurs early or late in a subject in need thereof, and progressive myocardial injury-preventing compositions that contain a chemotactic hematopoietic stem cell product, and, optionally, an additional active agent. The method treats ongoing vascular insufficiency affecting coronary circulation by (i) stimulating neoangiogenesis in a peri-infarct border zone, thereby improving myocardial perfusion; and, (ii) through a paracrine effect, preventing apoptosis of cardiomyocytes in the peri-infarct border zone. The neoangiogenesis and paracrine-mediated reduction of apoptosis reduces progressive myocardial cell loss, which leads to improvement in cardiac function and a reduction of risk of major adverse cardiovascular events.Type: GrantFiled: March 12, 2013Date of Patent: January 3, 2017Assignee: Amorcyte, LLCInventors: Andrew L. Pecora, Robert A. Preti
-
Patent number: 9533011Abstract: Described herein are tissue grafts derived from the placenta. The grafts are composed of at least one layer of amnion tissue where the epithelium layer has been substantially removed in order to expose the basement layer to host cells. By removing the epithelium layer, cells from the host can more readily interact with the cell-adhesion bio-active factors located onto top and within of the basement membrane. Also described herein are methods for making and using the tissue grafts. The laminin structure of amnion tissue is nearly identical to that of native human tissue such as, for example, oral mucosa tissue. This includes high level of laminin-5, a cell adhesion bio-active factor show to bind gingival epithelia-cells, found throughout upper portions of the basement membrane.Type: GrantFiled: February 3, 2014Date of Patent: January 3, 2017Assignee: MiMedx Group, Inc.Inventors: John Daniel, Randall Spencer, John Russo, Robert Tofe
-
Patent number: 9533012Abstract: A method for enhancing the therapeutic effect of a stem cell is provided. The method comprises treating the stem cell with ligustilide, wherein the treatment is conducted in a culture medium of the stem cell. A method of stem cell treatment is also provided, comprising administering to a subject in need an effective amount of a stem cell or a combination of ligustilide and a stem cell, wherein the stem cell has been treated with ligustilide.Type: GrantFiled: November 24, 2014Date of Patent: January 3, 2017Assignee: GWO XI STEM CELL APPLIED TECHNOLOGY CO., LTD.Inventors: Shinn-Zong Lin, Horng-Jyh Harn, Ru-Huei Fu, Shih-Ping Liu, Po-Cheng Lin, Ming-Hsi Chuang
-
Patent number: 9533013Abstract: A method of repairing diseased or dysfunctional pancreas or liver is provided. The method involves preparation of a suspension of stem cells and/or progenitor cells such as biliary tree stem cells, hepatic stem cells, pancreatic stem cells or their descendants, committed progenitor cells, from healthy tissue of the patient or of the biliary tree of a non-autologous donor and engrafting the cells into the wall of bile ducts near to the organ to be treated. The graft consists of stem cells or progenitors that are admixed with biomaterials and, optionally, with cytokines and/or native epithelial-mesenchymal cells appropriate for the maturational lineage stage of the cells to be engrafted.Type: GrantFiled: March 12, 2014Date of Patent: January 3, 2017Assignees: University of North Carolina at Chapel Hill, Sapienza Università Di Roma, University of Miami—Diabetes Research InstituteInventors: Lola M. Reid, Yunfang Wang, David A. Gerber, Giacomo Lanzoni, Luca Inverardi, Juan Dominguez-Bendala, Domenico Alvaro, Vincenzo Cardinale, Eugenio Gaudio, Guido Carpino
-
Patent number: 9533014Abstract: Provided are therapeutic compositions containing Ecobiotic™ populations for prevention, treatment and reduction of symptoms associated with a dysbiosis of a mammalian subject such as a human.Type: GrantFiled: January 8, 2015Date of Patent: January 3, 2017Assignee: Seres Therapeutics, Inc.Inventors: Matthew R. Henn, Geoffrey von Maltzahn, Anthony Mario D'Onofrio, Kevin Daniel Litcofsky, David Arthur Berry, David N. Cook, Noubar B. Afeyan, John Grant Aunins
-
Patent number: 9533015Abstract: New Lactococcus lactis strains, NRRL B-50571 and NRRL B-50572, and a bacterial preparation containing the same, have the ability to produce bioactive peptides that reduce blood pressure, lower LDL-cholesterol (bad cholesterol) and present antioxidant properties for better cardiovascular health. These biologically active peptides may be produced within the food for the production of a food product, such as a functional food, or they may be produced from protein sources and subsequently added to a food as part of the formulation or as part of a food supplement or a pharmaceutical preparation.Type: GrantFiled: October 27, 2014Date of Patent: January 3, 2017Assignees: Centro De Investigación En Alimentación Y Desarrollo, A.C. (CIAD)Inventors: Belinda Vallejo Galland, Aarón Fernando González Córdova, Jóse Carlos Rodríguez Figueroa
-
Patent number: 9533016Abstract: New Lactococcus lactis strains, NRRL B-50571 and NRRL B-50572, and a bacterial preparation containing the same, have the ability to produce bioactive peptides that reduce blood pressure, lower LDL-cholesterol (bad cholesterol) and present antioxidant properties for better cardiovascular health. These biologically active peptides may be produced within the food for the production of a food product, such as a functional food, or they may be produced from protein sources and subsequently added to a food as part of the formulation or as part of a food supplement or a pharmaceutical preparation.Type: GrantFiled: October 28, 2014Date of Patent: January 3, 2017Assignees: Centro De Investiagción En Alimentación Y Desarrollo, A.C. (CIAD)Inventors: Belinda Vallejo Galland, Aarón Fernando González Córdova, Jóse Carlos Rodríguez Figueroa
-
Patent number: 9533017Abstract: The present invention relates to the Saccharomyces Cerevisiae strain deposited with the French National Collection of Micro-organism Cultures under number CNCM I-3856, or a Saccharomyces cerevisiae yeast obtained by culturing said strain for the use thereof in the prevention and/or treatment of vaginal mycoses, and in particular vaginal candidiasis.Type: GrantFiled: July 9, 2013Date of Patent: January 3, 2017Assignee: LESAFFRE ET COMPAGNIEInventor: Pascal Vandekerckove
-
Patent number: 9533018Abstract: The invention discloses a method of processing Antrodia cinnamomea for producing a processed sample of Antrodia cinnamomea, which easily releases antcin K in a following extraction process. The method includes the steps of: soaking a raw sample of Antrodia cinnamomea with a processing reagent comprising 25-83.3 wt % of rice vinegar and 16.7-75 wt % of yellow wine at 22-28° C. for 22-26 hours; and steaming the soaked product at 1-3 kg/cm2, 110-150° C. for 10-50 minutes.Type: GrantFiled: May 29, 2015Date of Patent: January 3, 2017Assignee: HAN SHENG BIOTECH CO., LTDInventors: Shorong-Shii Liou, I-Min Liu
-
Patent number: 9533019Abstract: The Calotropis Procera extracts as anti-ulcerative colitis agents include extracts of Calotropis procera obtained by a method comprising the following steps: (a) providing a plant material derived from Calotropis procera, (b) drying the plant material, (c) pulverizing the plant material to provide a fine powder; and (d) extracting the plant material by percolation using 95% aqueous alcohol in a container to obtain an alcoholic extract. A method of treating ulcerative colitis comprises administering a therapeutically effective amount of an alcoholic extract of C. procera to a patient in need thereof.Type: GrantFiled: March 2, 2016Date of Patent: January 3, 2017Assignee: KING SAUD UNIVERSITYInventors: Amani Shafeek Awaad, Ghada Mohamed Zain, Reham M. El-Meligy, Haya Fahd Alkanhal, Vidya Devenathadesikan Seshadri
-
Patent number: 9533020Abstract: The present invention relates to a pharmaceutical composition for treating thermal injuries and wounds combined with bone injuries. More specifically, the present invention relates to a pharmaceutical composition for treating thermal injuries and wounds combined with bone injuries characterized in consisting of 4%-12% beeswax and 88%-96% sesame oil extract containing such raw materials as Radix Scutellaria, Coptis Chinensis, Cortex Phellodendri, Pericarpium Papaveris and Lumbricus by weight based on the total weight of the said composition, wherein the content of Radix Scutellaria, Coptis Chinensis, Cortex Phellodendri, Pericarpium Papaveris or Lumbricus based on their dry weight is respectively 1%-6% of the total weight of sesame oil.Type: GrantFiled: May 29, 2013Date of Patent: January 3, 2017Inventor: Kevin Peng Xu
-
Patent number: 9533021Abstract: A nutritional supplement for inhibiting sensorineural hearing loss includes from about 0.25 to about 6.0 wt. % thiamin, from about 0.1 to about 10 wt. % pyridoxiyl-5-phosphate, from about 0.01 to about 10 wt. % folic acid, from about 0.025 to about 4.0 wt. % hydroxycobalamin, from about 1 to about 7 wt. % magnesium, from about 0.25 to about 6.0 wt. % zinc, from about 0.001 to about 0.02 wt. % selenium, from about 0.1 to about 10 wt. % manganese, from about 5 to about 50 wt. % ginger root P.E. 4:1, from about 5 to about 40 wt. % citrus bioflavonoids, from about 2.5 to about 40 wt. % 1-cystine, from about 5 to about 40 wt. % n-acetlyl-1-carnitine, from about 1 to about 40 wt. % alpha lipoic acid, from about 1 to about 40 wt. % coenzyme Q10, from about 1 to about 40 wt. % green tea extract, and from about 1 to about 60 wt. % resveratrol.Type: GrantFiled: September 18, 2013Date of Patent: January 3, 2017Assignee: Sustain Biologics, LLCInventor: Ford D. Albritton, IV
-
Patent number: 9533022Abstract: Provided herein are methods for the treatment of type I diabetes, Type II diabetes, metabolic syndrome, or obesity, or of appetite suppression, or for mitigating insulin resistance, or for reducing an undesirably high fasting serum glucose level, or for reducing an undesirably high peak serum glucose level, or for reducing an undesirably high peak serum insulin level, or for reducing an undesirably large response to a glucose tolerance test in synergistic combination with metformin. Treatment is effected with a combination therapy of metformin and a peptide with a sequence selected from SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, and SEQ ID NO: 24 administered to a patient.Type: GrantFiled: February 27, 2015Date of Patent: January 3, 2017Assignee: KeyBioscience A/SInventors: Nozer M. Mehta, William Stern, Amy M. Sturmer, Morten Asser Karsdal, Kim Henriksen
-
Patent number: 9533023Abstract: The present invention relates to modified eIF4G1 peptides, uses thereof and pharmaceutical compositions comprising the modified eIF4G1 peptides.Type: GrantFiled: March 31, 2015Date of Patent: January 3, 2017Assignee: Agency for Science, Technology and ResearchInventors: Christopher John Brown, Cheng San Brian Chia
-
Patent number: 9533024Abstract: Methods and compositions for the biological repair of cartilage using a hybrid construct combining both an inert structure and living core are described. The inert structure is intended to act not only as a delivery system to feed and grow a living core component, but also as an inducer of cell differentiation. The inert structure comprises concentric internal and external and inflatable/expandable balloon-like bio-polymers. The living core comprises the cell-matrix construct comprised of HDFs, for example, seeded in a scaffold. The method comprises surgically removing a damaged cartilage from a patient and inserting the hybrid construct into the cavity generated after the foregoing surgical intervention. The balloons of the inert structure are successively inflated within the target area, such as a joint, for example. Also disclosed herein are methods for growing and differentiating human fibroblasts into chondrocyte-like cells via mechanical strain.Type: GrantFiled: May 7, 2010Date of Patent: January 3, 2017Assignee: Spinalcyte, LLCInventors: Lionel C. Sevrain, Sylvie Y. Verdier-Sevrain
-
Patent number: 9533025Abstract: A method of ameliorating, inhibiting, preventing, or reducing male infertility in a subject undergoing or in need of chemotherapy by administering to the subject a granulocyte colony-stimulating factor in a protective amount, prior to, during or after administration of one or more chemotherapeutic agents to the subject.Type: GrantFiled: February 10, 2014Date of Patent: January 3, 2017Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMInventor: Brian P. Hermann
-
Patent number: 9533026Abstract: In certain embodiments, this present invention provides polypeptide compositions, including compositions containing a modified polypeptide, and methods for inhibiting Ephrin B2 or EphB4 activity. In other embodiments, the present invention provides methods and compositions for treating cancer or for treating angiogenesis-associated diseases.Type: GrantFiled: May 6, 2013Date of Patent: January 3, 2017Assignee: VASGENE THERAPEUTICS, INCInventors: Valery Krasnoperov, Nathalie Kertesz, Ramachandra Reddy, Parkash Gill, Sergey Zozulya
-
Patent number: 9533027Abstract: Compositions of matter and methods for making, storing and administering artificial blood substitutes. Artificial blood substitutes may have oxygen carriers that encapsulate an oxygen-binding compound in a polymer vesicle. Oxygen-binding compounds may include hemoglobin, myoglobin, or other oxygen binding compounds having characteristics similar to hemoglobin. Oxygen carriers may include nanoparticles, polymers and/or polymersomes comprising of poly(ethylene oxide)-block-poly(?-caprolactone) (PEO-b-PCL) and related diblock copolymers of poly(ethylene oxide)-block-poly(?-methyl ?-caprolactone) (PEO-b-PMCL). The oxygen carriers may have tunable oxygen-binding capacities, uniform and appropriately small size distributions, and human bloodlike viscosities and oncotic properties.Type: GrantFiled: July 24, 2014Date of Patent: January 3, 2017Assignee: Vindico NanoBioTechnology, LLCInventors: P. Peter Ghoroghchian, Eric Ostertag
-
Patent number: 9533028Abstract: The invention provides polypeptides comprising a complement factor B analog. The invention also provides various complement factor B analogs including complement factor B analogs comprising a mutation of a free cysteine amino acid and related methods, nucleic acids and vectors. These complement factor B analogs and related methods, nucleic acids and vectors can be used to modulate a complement pathway or for the study and/or treatment of various conditions or diseases related to a complement pathway.Type: GrantFiled: November 25, 2015Date of Patent: January 3, 2017Assignee: Wellstat ImmunoTherapeutics, LLCInventors: ChangHung Chen, Michael Kaleko, Beibei Li, Tianci Luo, Jeffrey Allan Miller, Ruigong Wang
-
Patent number: 9533029Abstract: Methods are disclosed herein for treating depression in the subject. A method includes the use of Botulinum toxin to cause paralysis of a facial muscle, such as the depressor anguli oris, procerus, frontalis, orbicularis oculi, or corrugator supercilii muscle to treat depression in the subject.Type: GrantFiled: June 22, 2015Date of Patent: January 3, 2017Inventor: Eric Finzi
-
Patent number: 9533030Abstract: The present invention relates to a vaccine capable to induce the formation of antibodies directed to PCSK9 in vivo.Type: GrantFiled: August 28, 2013Date of Patent: January 3, 2017Assignee: AFFIRIS AGInventors: Sylvia Brunner, Gergana Galabova, Gabriele Winsauer, Erika Bilcikova, Claudia Juno, Pola Linzmayer-Hirt, Birgit Schuh, Guenther Staffler
-
Patent number: 9533031Abstract: Disclosed are yeast-based immunotherapeutic compositions comprising mucin-1 (MUC1), as well as methods for the prevention and/or treatment of cancers characterized by the expression or overexpression of mucin-1 (MUC1).Type: GrantFiled: March 14, 2013Date of Patent: January 3, 2017Assignees: GlobeImmune, Inc., The United States of America, as represented by the Secretary, Dept. of Health and Human ServicesInventors: Alex Franzusoff, Zhimin Guo, Jeffrey Schlom, Kwong-Yok Tsang
-
Patent number: 9533032Abstract: The invention relates to vaccine compositions having a carrier protein and an antigen of interest entrapped in a complex, methods of making such vaccines, and methods of vaccine administration.Type: GrantFiled: November 24, 2015Date of Patent: January 3, 2017Assignee: President and Fellows of Harvard CollegeInventor: John J. Mekalanos
-
Patent number: 9533033Abstract: The invention described herein relates to a Haemophilus influenzae (H. influenzae) regulon encoding type IV pili. In particular, the invention relates to type IV pili from nontypeable H. influenzae (NTHi) and from H. influenzae strains a, b, c, e and f. The invention provides isolated H. influenzae pilus polynucleotides and polypeptides encoded by the polynucleotides as well as polynucleotides and polypeptides encoded by the polynucleotides involved in the assembly/disassembly of the structure. The invention also relates to uses of these polynucleotides and/or polypeptides including methods for eliciting an immune response to H. influenzae and methods of treating and preventing H. influenzae related pathological conditions.Type: GrantFiled: March 7, 2016Date of Patent: January 3, 2017Assignee: NATIONWIDE CHILDREN'S HOSPITAL, INC.Inventors: Lauren O. Bakaletz, Robert S. Munson, Jr.
-
Patent number: 9533034Abstract: Provided are compositions and methods for use in prophylaxis of puerperal metritis and improving reproductive function of ruminants. The methods and compositions are for subcutaneous administration and are provided as veterinary compositions and as articles of manufacture. The veterinary composition can contain whole cells selected from whole cells of Escherichia coli (E. coli), Trueperella pyogenes (T. pyogenes), Fusobacterium necrophorum (F. necrophorum) and combinations thereof; and/or proteins selected from F. necrophorum leukotoxin (LKT), E. coli type 1 fimbrial adhesin (FimH), T. pyogenes pyolysin (PLO), and all combinations of the whole cells and the proteins.Type: GrantFiled: October 8, 2013Date of Patent: January 3, 2017Assignee: Cornell UniversityInventors: Rodrigo Carvalho Bicalho, Robert Owen Gilbert, Vinicius Machado, Marcela Bicalho
-
Patent number: 9533035Abstract: The invention relates to a truncated L1 protein of the Human Papillomavirus Type 11, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of condyloma acuminatum or HPV infections.Type: GrantFiled: May 29, 2008Date of Patent: January 3, 2017Assignees: XIAMEN UNIVERSITY, BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.Inventors: Jun Zhang, Jin Wang, Chunyan Yang, Ying Gu, Shaowei Li, Ningshao Xia
-
Methods for generating immune responses to influenza antigens with a secretable CD40L fusion protein
Patent number: 9533036Abstract: Provided are methods of generating an immune response to any of various antigens including foreign antigens such as infectious agent antigens. In general, the method comprises administering an expression vector encoding a transcription unit encoding a secretable fusion protein, the fusion protein containing the foreign antigen and CD40 ligand and also administering the encoded fusion protein. In another approach, an immune response to the foreign antigen is elicited using the encoded fusion protein without administering the vector. The invention methods may be used to immunize an individual against an infectious agent such as influenza virus. Methods of obtaining an immune response in older individuals also is described.Type: GrantFiled: November 6, 2006Date of Patent: January 3, 2017Assignee: MicroVAX, LLCInventors: Yucheng Tang, Albert Deisseroth -
Patent number: 9533037Abstract: The instant invention comprises a process of preparing a composition comprising directed sequence polymer (DSP) mixtures that act as epitopes and useful as vaccines, such DSP synthesized according to a set of rules regarding the identity and the frequency of occurrence of amino acids that substitute a base or native amino acid of a known epitope. The resulting composition is a mixture of related peptides for therapeutic use as a vaccine, preferably for infectious agents that are immune evasive.Type: GrantFiled: October 16, 2008Date of Patent: January 3, 2017Assignee: Declion Holdings LLCInventors: Dustan Bonnin, Eric Zanelli, Jeff Krieger, Thomas Mathers
-
Patent number: 9533038Abstract: This invention relates to soluble forms of G glycoprotein from Hendra and Nipah virus. In particular, this invention relates to compositions comprising soluble forms of G glycoprotein from Hendra and Nipah virus and also to diagnostic and therapeutic methods using the soluble forms of G glycoprotein from Hendra and Nipah virus. Further, the invention relates to therapeutic antibodies including neutralizing antibodies, and vaccines for the prevention and treatment of infection by Hendra and Nipah viruses.Type: GrantFiled: April 30, 2015Date of Patent: January 3, 2017Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Christopher C. Broder, Katharine N. Bossart
-
Patent number: 9533039Abstract: The present invention provides antibodies that bind to CD48 and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human CD48. In certain embodiments, the antibodies of the present invention block the binding of CD48 to one or more CD48 receptor. The antibodies of the invention are useful, inter alia, for the treatment of diseases and disorders associated with one or more CD48 biological activities, including the treatment of allergic conditions and other inflammatory conditions, e.g., systemic lupus erythematosus.Type: GrantFiled: April 18, 2013Date of Patent: January 3, 2017Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Brendan J. Classon, Ana Kostic, Xunbao Duan
-
Patent number: 9533040Abstract: Methods to inhibit the formation of retrovirus integrase reaching dimers, to dissociate retrovirus integrase reaching dimers, and to stabilize retrovirus integrase reaching dimers in a conformation in which retrovirus DNA-to host cell DNA integration activity of the integrase is inhibited are provided. Methods for treating a retrovirus infection, which target retrovirus integrase reaching dimer formation and/or stability are also provided.Type: GrantFiled: June 21, 2013Date of Patent: January 3, 2017Assignee: Institute for Cancer ResearchInventors: Anna Marie Skalka, Mark Andrake, Ravi Shankar Bojja
-
Patent number: 9533041Abstract: The present invention relates to an inhibitor of NGAL gene expression or a NGAL antagonist for use in the prevention or the treatment of heart failure.Type: GrantFiled: December 5, 2011Date of Patent: January 3, 2017Assignee: Institut National de la Santé et de la Recherche MédicaleInventor: Frédéric Jaisser
-
Patent number: 9533042Abstract: The invention provides anti-Notch1 NRR antibodies, and compositions comprising and methods of using these antibodies.Type: GrantFiled: February 11, 2014Date of Patent: January 3, 2017Assignee: Genentech, Inc.Inventors: Christian W. Siebel, Yan Wu
-
Patent number: 9533043Abstract: An isolated truncated desmoglein 4 (DSG4) polypeptide splice variant of the invention is characterized by an amino acid sequence that lacks a region encoded before exon 9 or beyond exon 10 of the DSG4 gene having the polynucleotide sequence of SEQ ID NO: 75. Also disclosed is a method of diagnosing a cancer, or monitoring the course thereof, in a patient. The method comprises detecting in a tissue sample of a patient the expression of a tumor-associated antigen comprising the extracellular domain of a DSG4 polypeptide encoded by a DSG4 gene having the polynucleotide sequence of SEQ ID NO: 75, or a truncated DSG4 polypeptide splice variant characterized by an amino acid sequence that lacks a region encoded before exon 9 or beyond exon 10 of the DSG4 gene.Type: GrantFiled: September 25, 2013Date of Patent: January 3, 2017Assignee: BioNTech AGInventors: Özlem Türeci, Ugur Sahin, Sandra Schneider, Gerd Helftenbein, Volker Schlüter, Dirk Usener, Philippe Thiel, Michael Koslowski
-
Patent number: 9533044Abstract: Formulations of VLA-4 binding antibody are described.Type: GrantFiled: June 22, 2012Date of Patent: January 3, 2017Assignee: BIOGEN MA INC.Inventor: Kevin Maloney
-
Patent number: 9533045Abstract: The present invention provides methods, systems, and devices for performing photothermal therapy (e.g., to treat cancer) using photothermal nanoparticles with a biocompatible coating surrounding a highly crystallized Fe3O4 core. In certain embodiments, the highly crystallized Fe3O4 core of the photothermal nanoparticles has an X-ray diffraction (XRD) pattern where the brightest diffraction ring is from the 440 plane. In some embodiments, the photothermal therapy is conducted with a device configured to emit electromagnetic radiation in the wavelengths between about 650 nm and 1000 nm, wherein the device further comprises a visible light source that allows a user to determine where the electromagnetic radiation is contacting a subject.Type: GrantFiled: August 12, 2014Date of Patent: January 3, 2017Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Hongwei Chen, Duxin Sun
-
Patent number: 9533046Abstract: The current invention provides a controlled release oral solid formulation of levodopa comprising levodopa, a decarboxylase inhibitor, and a carboxylic acid. Also provided by this invention is multiparticulate, controlled release oral solid formulations of levodopa comprising: i) a controlled release component comprising a mixture of levodopa, a decarboxylase inhibitor and a rate controlling excipient; ii) a carboxylic acid component; and iii) an immediate release component comprising a mixture of levodopa and a decarboxylase inhibitor.Type: GrantFiled: December 4, 2015Date of Patent: January 3, 2017Assignee: Impax Laboratories, Inc.Inventors: Ann Hsu, Jim Kou, Laman Alani
-
Patent number: 9533047Abstract: Provided are formulations, compositions and methods for delivering biological moieties such as modified nucleic acids into cells to modulate protein expression. Such compositions and methods include the delivery of biological moieties, and are useful for production of proteins.Type: GrantFiled: July 22, 2014Date of Patent: January 3, 2017Assignee: MODERNATX, INC.Inventors: Antonin de Fougerolles, Sayda M. Elbashir
-
Patent number: 9533048Abstract: The present invention provides a composition comprising or consisting of components (a) (i) at least one mono-alkanoyl glycerol ester, wherein alkanoyl is selected from C4 to C21 alkanoyl, preferably from octanoyl and decanoyl; and (b) (i) at least one compound selected from cholesterol, phosphatidyl cholines and phosphatidyl glycerols, wherein the acyl moieties of the phosphatidyl moieties are independently selected from C6 to C21 alkanoyl and C6 to C21 alkenoyl.Type: GrantFiled: May 25, 2012Date of Patent: January 3, 2017Assignee: ARISGEN SAInventors: Paolo Botti, Sylvie Tchertchian
-
Patent number: 9533049Abstract: The invention relates to a method for preparing nanoparticles based on functional amphiphilic molecules or macromolecules, optionally in the presence of at least one colipide, enabling the encapsulation of therapeutic agents, especially anti-tumoral agents, and the use thereof for the transport and vectorization of therapeutic agents, especially anti-tumoral agents.Type: GrantFiled: March 13, 2014Date of Patent: January 3, 2017Assignees: UNIVERSITE D'AIX-MARSEILLE, UNIVERSITE DE BORDEAUX, UNIVERSITÉ DE BOURGOGNEInventors: Philippe Barthelemy, Michel Camplo, Nathalie Campins, Bruno Chauffert, Florence Bouyer
-
Patent number: 9533050Abstract: The invention relates to a sustained-release vaginal ring which includes meloxicam and an agent for modulating the release of the active principle, such as polyvinylpyrrolidone K-30, which releases the active principle over at least 90 days and which can be used as a continuous-use contraceptive in women. The vaginal ring preferably includes 5 wt % to 30 wt % of meloxicam, relation to total weight of the formulation.Type: GrantFiled: December 29, 2011Date of Patent: January 3, 2017Assignee: LABORATORIOS ANDROMACO S.A.Inventors: Shu-Chen Chen, Marianela del Carmen Beltran Apablaza
-
Patent number: 9533051Abstract: The subject invention pertains to formulations comprising poly(menthyl acrylate) nanoparticles comprising at least one active ingredient contained in a plurality of hydrophobic carriers and dispersed in an aqueous medium. The subject invention further pertains to methods of polymerization of drug loaded nanoparticles made up of methyl acrylate monomers in an aqueous emulsion.Type: GrantFiled: December 3, 2015Date of Patent: January 3, 2017Assignee: University of South FloridaInventors: Edward Turos, Faeez Sisan Mahzamani, Ashleigh Brooke Bachman, Kristy Lineth Flores
-
Patent number: 9533052Abstract: The invention provides an ophthalmic product containing rebamipide, which has a transparency enough to be agreeable feeling on using it and has neutral so weakly acidic pH not to injury of the keratoconjunctiva of a patient suffering from dry eye. An aqueous suspension of crystalline rebamipide which has an improved transparency is provided by adding an aqueous solution of rebamipide dissolved by a base such as sodium hydroxide or an aqueous solution of a salt of rebamipide to an aqueous acidic solution such as hydrochloric acid containing at least one of the compounds selected from water-soluble polymers and surfactants, and mixing them.Type: GrantFiled: October 19, 2015Date of Patent: January 3, 2017Assignee: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Takakuni Matsuda, Shogo Hiraoka, Yuso Tomohira, Shinichi Ishikawa
-
Patent number: 9533053Abstract: The present invention is an ophthalmic composition containing a relatively high concentration of olopatadine. The composition is typically an ophthalmic aqueous solution containing relatively high concentrations of olopatadine solubilized within the solution. The composition is preferably capable of providing enhanced relief from symptoms of ocular allergic conjunctivitis, particularly late phase symptoms of ocular allergic conjunctivitis.Type: GrantFiled: June 13, 2014Date of Patent: January 3, 2017Assignee: Alcon Research, Ltd.Inventors: Daniel A. Gamache, Laman Alani, Malay Ghosh, Francisco Javier Galan, Nuria Carreras Perdiguer, Onkar N. Singh